Form 4: ALX Oncology Director Acquires 40,400 Stock Options

ALX Oncology Holdings Inc. Director Rekha Hemrajani reported the acquisition of 40,400 stock options with an exercise price of $1.32, vesting monthly starting February 20, 2026.

Summary

• Rekha Hemrajani, a Director of ALX Oncology Holdings Inc. (ALXO), acquired 40,400 stock options.
• The transaction date for the option grant was January 20, 2026.
• The exercise price for these stock options is $1.32 per share.
• The options will vest in 12 equal monthly installments, commencing on February 20, 2026.
• The expiration date for these stock options is January 19, 2036.
• Following this transaction, Rekha Hemrajani beneficially owns 40,400 derivative securities (stock options) directly.

Sentiment

Score: 7

Explanation: The acquisition of stock options by a director is generally viewed as a positive signal, indicating confidence in the company's future and aligning management interests with shareholders. It's a standard compensation practice, so not an overwhelmingly strong positive, but certainly not negative.

Positives

• A director acquiring stock options can signal confidence in the company's future performance and aligns their interests with those of shareholders.
• The grant of options is a common form of incentive compensation, potentially motivating the director to contribute to long-term value creation.

Future Outlook

The vesting schedule of the stock options, commencing in February 2026 and continuing for 12 months, indicates a future alignment of the director's financial interests with the company's long-term performance.

Industry Context

The grant of stock options to a director is a standard practice in the biotechnology and pharmaceutical industry, serving as a key component of executive and director compensation packages designed to incentivize long-term performance and align leadership interests with shareholder value.

Comparison to Industry Standards

• The grant of stock options to directors is a common compensation mechanism across publicly traded companies, particularly in growth-oriented sectors like biotechnology, similar to practices observed at companies such as Amgen or Gilead Sciences, where equity-based incentives are prevalent.
• The vesting schedule over 12 months is a typical structure for such grants, aiming to retain talent and ensure sustained commitment, comparable to vesting schedules seen in similar grants at peer companies.

Stakeholder Impact

• Shareholders: The transaction aligns the director's financial interests with shareholder value creation, potentially leading to more focused long-term decision-making.
• Employees: No direct impact on employees is indicated by this specific filing.

Next Steps

• The stock options will begin vesting in 12 equal monthly installments starting February 20, 2026.

Key Dates

Recommendation

The acquisition of stock options by a director is a positive signal, suggesting insider confidence and alignment of interests. However, a single Form 4 filing, while informative, does not provide sufficient fundamental data to warrant a strong 'buy' or 'sell' recommendation. It supports a 'hold' stance, indicating that existing investors may find reassurance in this insider activity, but new investors should conduct further due diligence.

Keywords

ALX Oncology, ALXO, Form 4, Stock Options, Director Compensation, Insider Transaction, Beneficial Ownership